Table of contents

Clinical/translational cancer immunotherapy

• Original research:

  Poor clinical outcomes and immunoevasive contexture in CD161⁺CD8⁺ T cells barren human pancreatic cancer

  (26 March, 2024)

  Qiangda Chen, Hanlin Yin, Zhenlai Jiang, Taochen He, Yuqi Xie, Weilin Mao, Jiande Han, Siyao Liu, Wenhui Lou, Wenchuan Wu, Joseph R Habib, Jun Yu, Liang Liu, Ning Pu
• Original research: Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis (26 March, 2024)

  Jimmy S Patel, Yena Woo, Amber Draper, Caroline S Jansen, Jennifer W Carlisle, Pasquale F Innominato, Francis A Lévi, Layla Dhabaan, Viraj A Master, Mehmet A Bilen, Mohammad K Khan, Michael C Lowe, Haydn Kissick, Zachary S Buchwald, David C Qian
• Original research: Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells (21 March, 2024)

  Maxim Yankelevich, Archana Thakur, Shakeel Modak, Roland Chu, Jeffrey Taub, Alissa Martin, Dana Schalk, Amy Schienshang, Sarah Whitaker, Katie Rea, Daniel W Lee, Qin Liu, Anthony F Shields, Nai-Kong V Cheung, Lawrence G Lum
• Original research: Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06) (13 March, 2024)

  Ju Won Kim, Hyo Jin Lee, Ji Yoon Lee, Sook Ryun Park, Yu Jung Kim, In Gyu Hwang, Woo Kyun Bae, Jae Ho Byun, Jung Sun Kim, Eun Joo Kang, Jeeyun Lee, Sang Joon Shin, Won Jin Chang, Eun-Ok Kim, Jason K Sa, Kyong Hwa Park
• Original research: Efficacy, safety, and biomarker analyses of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with advanced non-small cell lung cancer (13 March, 2024)

  Arun Rajan, Houssein Abdul Sater, Osama Rahma, Richy Agajanian, Wiem Lassoued, Jennifer L Marté, Yo-Ting Tsai, Renee N Donahue, Elizabeth Lamping, Shania Bailey, Andrew Weisman, Beatriz Walter-Rodriguez, Rena Ito, Yulia Vugmeyster, Masashi Sato, Andreas Machl, Jeffrey Schlom, James L Gulley
• Original research: Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial (13 March, 2024)

  Heinz-Josef Lenz, Aparna Parikh, David R Spigel, Allen L Cohn, Takayuki Yoshino, Mark Kochenderfer, Elena Elez, Spencer H Shao, Dustin Deming, Regan Holdridge, Timothy Larson, Eric Chen, Amit Mahipal, Antonio Ucar, Dana Cullen, Edwina Baskin-Bey, Tong Kang, Amy B Hammell, Jin Yao, Josep Tabernero
• Original research: Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial (13 March, 2024)

  Dirk Schadendorf, Jason John Luke, Paolo A Ascierto, Georgina V Long, Piotr Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz-Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
• Original research: Mefloquine enhances the efficacy of anti-PD-1 immunotherapy via IFN-γ-STAT1-IRF1-LPCAT3-induced ferroptosis in tumors (11 March, 2024)

  Qian Tao, Nian Liu, Jie Wu, Jing Chen, Xiang Chen, Cong Peng
• Original research: High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma (11 March, 2024)

  Danny Rischin, Brett G M Hughes, Nicole Basset-Séguin, Dirk Schadendorf, Samantha Bowyer, Sabiha Trabelsi Messai, Friedegund Meier, Thomas K Eigentler, Victoria Casado Echarren, Brian Stein, Marie Beylot-Barry, Sophie Dalac, Brigitte Dréno, Michael R Migden, Axel Hauschild, Chrysalyne D Schmults, Annette M Lim, Suk-Young Yoo, Anne J Paccaly, Apostolos Papachristos, Jenny-Hoa Nguyen, Emmanuel Okoye, Frank Seebach, Jocelyn Booth, Israel Lowy, Matthew G Fury, Alexander Guminski
• Original research: Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis (7 March, 2024)

  Katsuhiko Nara, Satoru Taguchi, Sebastiano Buti, Taketo Kawai, Yukari Uemura, Takehito Yamamoto, Haruki Kume, Tappei Takada
• Original research: Neoadjuvant chemoradiotherapy combined with sequential perioperative toripalimab in locally advanced esophageal squamous cell cancer (7 March, 2024)

  Xin Xu, Zhiyong Sun, Qiang Liu, Yao Zhang, Lei Shen, Chenpeng Zhang, Haiping Lin, Bin Hu, Ling Rong, Haiyan Chen, Xiaohang Wang, Xiaojing Zhao, Yong-Rui Bai, Qing Ye, Xiumei Ma
• Original research: Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors (7 March, 2024)

  Nikhil I Khushalani, Patrick A Ott, Robert L Ferris, Tina Cascone, Dirk Schadendorf, Dung T Le, Manish R Sharma, Fabrice Barlesi, William Sharfman, Jason J Luke, Ignacio Melero, Deanne Lathers, Jaclyn Neely, Satyendra Suryawanshi, Abanti Sanyal, James L Holloway, Rasika Suryawanshi, Scott Ely, Neil H Segal
• Original research: Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes (5 March, 2024)

  Amin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, Serena Rahme, Caiwei Zhong, Lucia Kwak, Marita Salame, Elias Bou Farhat, Dory Freeman, Edward El-Am, Arjun Ravishankar, Bachar Ahmad, Frank Aboubakar Nana, David Kaldas, Abdul Rafeh Naqash, Elad Sharon, Nicole R LeBoeuf, Alessio Cortellini, Andrea Malgeri, Shruti Gupta, Ahmad Al-Hader, Jeffrey A Sparks, Jenny Linnoila, Ole-Petter R Hamnvik, Tarek H Mouhieddine, Thomas Marron, Kaushal Parikh, Rana R McKay, Thomas Dilling, Toni K Choueiri, Elio Adib, Elie Najem, So Yeon Kim, Guru Sonpavde